Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models
Compose a Response to This Article
Other responses
No responses have been published for this article.